Keyword: Kymriah (tisagenlecleucel)
NICE rejected Novartis' Kymriah in adults with relapsed or refractory diffuse large B-cell lymphoma after two prior therapies.
Juno didn't immediately report CAR-T trial deaths, investors argued in a lawsuit, and now the sides have inked a $24 million settlement.
England's cost-effectiveness watchdogs gave Novartis the go-ahead for its CAR-T drug, Kymriah, to treat leukemia.
In a busy week at the European Commission, Novartis’ Kymriah, Gilead’s Yescarta, Jazz's Vyxeos, Alnylam's Onpattro and others got approvals.
The CAR-T drug is a "step-change" for patients with no other options, but it's too pricey to cover routinely, the cost watchdog said.
Novartis will initially add 260 workers at a new plant in Switzerland to make Kymria and add up to 450 more over time.
Novartis, whose CAR-T cancer treatment Kymriah was approved less than a year ago, today it has run into some manufacturing issues.
CMS has pulled the plug on a plan to implement indication-specific pricing on Novartis' CAR-T drug Kymriah.
Gilead and Novartis CAR-T cancer drugs Yescarta and Kymriah won an EMA committee backing for marketing approval.
The cost of new cancer drug rollouts—$200,000 on average last year—is helping drive treatment costs toward $100 billion annually in the U.S. alone.